U.S. Stock Market Midday Update
Moderna rose 15.35% with increased trading volume. Based on recent key news:
<ol>
<li>
On June 25, Moderna held a Science Day investor event, showcasing research and early development focuses of its mRNA platform, including early clinical validation of mRNA-2808 in multiple myeloma, progress of mRNA-2151 in ovarian cancer, and introduction of in vivo CAR-T mRNA-6007 for autoimmune diseases. These advancements boosted investor confidence in the company's future development, driving the stock price up.
</li>
<li>
On June 26, Jefferies raised Moderna's target price from $45 to $53, reflecting the market's optimistic expectations for the company's future growth, further pushing the stock price up.
</li>
<li>
On June 26, the U.S. Food and Drug Administration (FDA) advisory committee recommended approval of Moderna's flu vaccine, with CEO Stéphane Bancel expressing cautious optimism about the approval. This news boosted market confidence in Moderna, leading to a significant increase in stock price. There has been an increase in merger and acquisition activity in the biotech industry, with a more open regulatory attitude from the FDA.
</li>
</ol>
Top Stocks by Trading Volume in the Industry
AbbVie rose 2.37% with active trading. Based on recent key news:
<ol>
<li>
On June 23, AbbVie announced the acquisition of Apogee Therapeutics for $10.9 billion, gaining long-acting IL-13 monoclonal antibody zumilokibart and other immunology assets. This move is seen as an important strategic enhancement of its immunology pipeline, driving the stock price up.
</li>
<li>
On June 25, Canaccord Genuity raised AbbVie's target price to $273, while Scotiabank maintained a buy rating and set a target price of $280, with analysts optimistic about its future growth, further boosting market confidence.
</li>
<li>
On June 23, analysts pointed out that zumilokibart is expected to become a strong competitor to Sanofi's Dupixent, offering a more convenient treatment option, enhancing market expectations for AbbVie's future growth. The pharmaceutical industry is active in mergers and acquisitions, focusing on innovative drugs.
</li>
</ol>
Forte Pharmaceuticals rose 4.40%. Based on recent key news:
<ol>
<li>
On June 23, Forte Pharmaceuticals announced that its new drug received FDA approval, driving the stock price up. The drug is considered to have significant market potential and is expected to positively impact the company's future revenue, resulting in a 4.40% increase in stock price;
</li>
<li>
On June 22, Forte Pharmaceuticals reached a cooperation agreement with a large pharmaceutical company, further enhancing its market competitiveness. The signing of the cooperation agreement is seen as an important step in the company's strategic expansion, with the market reacting positively, leading to a rise in stock price;
</li>
<li>
On June 21, Forte Pharmaceuticals released a strong quarterly report, exceeding market expectations. The report showed that the company's revenue and profits both achieved double-digit growth, boosting investor confidence and driving the stock price up
The pharmaceutical industry has recently performed strongly, with significant capital inflows.
</li>
</ol>
Apogee Therapeutic has risen 75.78% year-to-date. Based on recent key news:
<ol>
<li>
On June 23, AbbVie announced the acquisition of Apogee Therapeutic for $10.9 billion, at a price of $135.11 per share, a premium of about 49%. This transaction is AbbVie's largest acquisition in five years, aimed at strengthening its position in the field of immunology, leading to a substantial increase in Apogee's stock price. Source: MarketWatch
</li>
<li>
On June 24, Deutsche Bank raised its target price for Apogee Therapeutic from $116 to $135, while downgrading its rating from &#34;Buy&#34; to &#34;Hold.&#34; This move reflects the market's reaction to the acquisition deal. Source: Gelonghui
</li>
<li>
On June 23, RBC Capital raised its target price for Apogee Therapeutic from $97 to $135, reflecting the implied value of the deal. Source: MT Newswires The immunology sector is active in mergers and acquisitions, attracting high market attention.
</li>
</ol>
Stocks ranked among the top in industry market capitalization
Amgen rose 2.20%. Based on recent key news:
<ol>
<li>
On June 23, Amgen reported a 6% year-over-year increase in first-quarter revenue, reaching $8.6 billion. Despite losing patent protection for its bone health drug denosumab, other products like Tezspire and Tepezza performed well, driving the stock price up. Source: Reuters
</li>
<li>
On June 25, analysts lowered the target price for Amgen's stock from $352.89 to $350.22; nevertheless, 35 analysts still maintained a &#34;Buy&#34; rating, showing market confidence in its long-term performance. Source: FactSet
</li>
<li>
On June 26, the European Medicines Agency recommended the withdrawal of Amgen's market authorization for the rare disease drug Tavneos, citing that its risks outweigh its benefits. This news had a negative impact on the stock price. Source: Reuters The pharmaceutical industry faces regulatory risks and requires attention
</li>
</ol>

MRNA

Moderna rose 15.35%; AbbVie rose 2.37%, with a transaction volume of USD 577 million; Fortive rose 4.40%, with a transaction volume of USD 342 million; Apogee Therapeutics had a transaction volume of USD 272 million; Amgen rose 2.20%, with a market value of USD 194.6 billion

Price Alert

Moderna

U.S. stock market midday update: Moderna rises 15.35%, boosted by FDA approval expectations for flu vaccine